Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ana.25523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of Plasma Neurodegenerative Biomarkers for Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy in Chinese Patients with Hepatic Cirrhosis.
J Clin Transl Hepatol
January 2025
Department of Infectious Diseases, Tongji Hospital, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Background And Aims: The performance of neurodegenerative biomarkers-neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1)-in diagnosing minimal hepatic encephalopathy (MHE) has not been systematically evaluated, simultaneously, nor have their associations with the development of overt hepatic encephalopathy (OHE). This study aimed to evaluate the performance of plasma NfL, GFAP, tau, and UCHL1 in diagnosing MHE and predicting the development of OHE in Chinese patients with hepatic cirrhosis.
Methods: In this prospective study, 124 patients with hepatic cirrhosis were recruited.
Peripheral neurofilament light chain and intracortical myelin in bipolar I disorder.
J Affect Disord
January 2025
Centre for Clinical Neurosciences, McMaster University, Canada; Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada; Mood Disorders Treatment and Research Centre and Women's Health Concerns Clinic, St. Joseph's Healthcare Hamilton, ON, Canada. Electronic address:
Background: Neurofilament light chain (NfL) is a cytoskeletal protein that supports neuronal structure. Blood NfL levels are reported to be higher in diseases where myelin is damaged. Studies investigating intracortical myelin (ICM) in bipolar disorder (BD) have reported deficits in ICM maturation over age.
View Article and Find Full Text PDFNeurofilament light chain (Nf-L) in cerebrospinal fluid and serum as a potential biomarker in the differential diagnosis of neurological diseases in cattle.
Vet Res
January 2025
Department of Veterinary Sciences, University of Turin, Largo Paolo Braccini 2-5, 10095, Grugliasco, TO, Italy.
Article Synopsis
- Neurofilament light chain (Nf-L) is identified as a potential biomarker for diagnosing neurological disorders in cattle, paralleling its established role in human neurology.
- The study found that Nf-L levels varied significantly between healthy and sick cattle, with consistent median levels detected in serum and cerebrospinal fluid (CSF) across different age groups.
- There is a promising association between Nf-L levels in serum and CSF, particularly in cattle with neurological disorders, indicating that Nf-L could serve as a valuable diagnostic tool in veterinary practices.
Early-Life Adversity Predicts Markers of Aging-Related Neuroinflammation, Neurodegeneration, and Cognitive Impairment in Women.
Ann Neurol
January 2025
Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Psychology, Berlin, Germany.
Objective: Despite the overwhelming evidence for profound and longstanding effects of early-life stress (ELS) on inflammation, brain structure, and molecular aging, its impact on human brain aging and risk for neurodegenerative disease is poorly understood. We examined the impact of ELS severity in interaction with age on blood-based markers of neuroinflammation and neurodegeneration, brain volumes, and cognitive function in middle-aged women.
Methods: We recruited 179 women (aged 30-60 years) with and without ELS exposure before the onset of puberty.
Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a "real-world" setting.
Ann Clin Transl Neurol
January 2025
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Objective: Patients with amyotrophic lateral sclerosis (ALS) caused by superoxide dismutase 1 (SOD1) gene mutations (SOD1 ALS) treated with tofersen have shown slowing of disease progression, and disease stabilization with recovery of function in some patients. We report our clinical experience with treating patients with SOD1 ALS and the effects of tofersen on outcome measures.
Methods: This was a single-center observational study of patients with SOD1 ALS receiving treatment with tofersen.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!